|
[1]World Health Organization.Hepatitis C 2009,http://www.who.int/mediacentre/factsheets/fs164/cn.2002 Nov;36(5 Suppl 1):S35-46.
|
|
[2]Seeff LB.Natural history of chronic hepatitis C[J].Hepatology,2002,36(5 Suppl 1):S35-46.
|
|
[3]McHutchison JG,Everson GT,Gordon SC,et al.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection[J].N Engl J Med,2009,360(18):1827-1838.
|
|
[4]Shiffman ML,Lawitz EJ,Zaman A,et al.PEG-IFN-l:antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection[J].Hepatology,2009,50(Suppl1):S237.
|
|
[5]Kenny-Walsh E.Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.Irish Hepatology Research Group[J].N Engl J Med,1999,340(16):1228-1233.
|
|
[6]Muller R.The natural history of hepatitis C:clinical experiences[J].J Hepatol,1996,24(2 Suppl):52-54.
|
|
[7]Sheppard P,Kindsvogel W,Xu W,et al.IL-28,IL-29 and their class II cytokine receptor IL-28R[J].Nat Immunol,2003,4(1):63-68.
|
|
[8]Kotenko SV,Gallagher G,Baurin VV,et al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex[J].Nat Immunol,2003,4(1):69-77.
|
|
[9]Sommereyns C,Paul S,Staeheli P,et al.IFN-lambda(IFNlambda)is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J].PLoS Pathog,2008,4(3):e1000017.
|
|
[10]Ge D,Fellay J,Thompson AJ,et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature,2009,461(7262):399-401.
|
|
[11]Kau A,Vermehren J,Sarrazin C.Treatment predictors of a sustained virologic response in hepatitis B and C[J].J Hepatol,2008,49(4):634-651.
|
|
[12]王东生,潘煜,牛俊奇,等.IL-28B基因变异与丙型肝炎的易感性及其自然清除的关系[J].临床肝胆病杂志,2010,26(5):496-499.
|
|
[13]McCarthy JJ,Li JH,Thompson A,et al.Replicated Association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin[J].Gastroenterology,2010,138(7):2307-2314.
|
|
[14]Montes-Cano MA,García-Lozano JR,Abad-Molina C,et al.Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes[J].Hepatology,2010,52(1):33-37.
|
|
[15]Tanaka Y,Nishida N,Sugiyama M,et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet,2009,41(10):1105-1109.
|
|
[16]Suppiah V,Moldovan M,Ahlenstiel G,et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet,2009,41(10):1100-1104.
|
|
[17]Rauch A,Kutalik Z,Descombes P,et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology,2010,138(4):1338-1345.
|
|
[18]Thomas DL,Thio CL,Martin MP,et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature,2009,461(7265):798-801.
|
|
[19]Grebely J,Petoumenos K,Hellard M,et al.Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection[J].Hepatology,2010,52(4):1216-1224.
|
|
[20]Rouch A,Rohrbach J,Bochuel PY,et al.The recent break throughs in the understanding of host genomics in hepatitis C[J].Eur J Clin Invest,2010,40(1):950-959.
|
|
[21]Sarasin-Filipowicz M,Oakeley EJ,Duong FH,et al.Interferon signaling and treatment outcome in chronic hepatitis C[J].Proc Natl Acad Sci U S A,2008,105(19):7034-7039.
|
|
[22]Urban TJ,Thompson AJ,Bradrick SS,et al.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C[J].Hepatology,2010,20[Epub ahead of print].
|
DownLoad: